The company
Pacira BioSciences, Inc.
PCRX · Nasdaq
Health CarePharmaceuticalsLeading
PCRX stood above a rising 150-day average in 17 of the last 52 weekly readings, including each of the last 9 weeks. It is 45.8% above that average now. Pharmaceuticals: 31% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 9 in a row
- Industry in uptrend
- 31% -7 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $4.3M
- Officials’ trades on record
- 17
- Institutions holding
- 231 (+14)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 17 of 52 weeks.
17 Apr – 16 Oct
Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
17 disclosed lines: House 16, Senate 0, executive 1; 3 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $15k–$50k | 30 Jan 2026filed 14 May 2026 |
| Tom Malinowski House: U.S. House ClerkNJ07 | bought | $1k–$15k | 6 May 2021filed 23 Jun 2021 |
| Tom Malinowski House: U.S. House ClerkNJ07 | bought | $1k–$15k | 20 Apr 2021filed 12 Jun 2021 |
| Tom Malinowski House: U.S. House ClerkNJ07 | bought | $1k–$15k | 25 Jan 2021filed 26 Aug 2021 |
| Tom Malinowski House: U.S. House ClerkNJ07 | bought | $1k–$15k | 15 Jan 2021filed 5 Mar 2021 |
| Tom Malinowski House: U.S. House ClerkNJ07 | bought | $1k–$15k | 2 Nov 2020filed 5 Mar 2021 |
| Tom Malinowski House: U.S. House ClerkNJ07 | bought | $15k–$50k | 26 Sep 2019filed 5 Mar 2021 |
| Tom Malinowski House: U.S. House ClerkNJ07 | bought | $1k–$15k | 23 Aug 2019filed 5 Mar 2021 |
| Tom Malinowski House: U.S. House ClerkNJ07 | bought | $15k–$50k | 31 May 2019filed 26 Aug 2021 |
| Tom Malinowski House: U.S. House ClerkNJ07 | bought | $15k–$50k | 31 May 2019filed 5 Mar 2021 |
| Tom Malinowski House: U.S. House ClerkNJ07 | bought | $15k–$50k | 30 May 2019filed 5 Mar 2021 |
| James B. Renacci House: U.S. House ClerkOH16 | bought | $15k–$50k | 13 Jan 2017filed 24 Jan 2017 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months17
Buyers · sellers0 · 5
| Who | Did | Shares | Traded |
|---|---|---|---|
| Lauren RikerSenior Vice President, Finance | sold | 6,000at $36.32 | 8 Oct 2026filed 9 Oct 2026 |
| Jonathan SloninChief Medical Officer | sold | 3,040at $23.23 | 17 Aug 2026filed 18 Aug 2026 |
| Lauren RikerSenior Vice President, Finance | sold | 6,115at $23.50 | 11 Jun 2026filed 12 Jun 2026 |
| Kristen WilliamsChief Administrative Officer | sold | 10,259at $22.27 | 4 Jun 2026filed 5 Jun 2026 |
| Shawn CrossChief Financial Officer | sold | 12,941at $25.16 | 23 Apr 2026filed 24 Apr 2026 |
| Shawn CrossChief Financial Officer | sold | 1,500at $25.01 | 22 Apr 2026filed 22 Apr 2026 |
| Shawn CrossChief Financial Officer | sold | 2,845at $25.01 | 21 Apr 2026filed 22 Apr 2026 |
| Shawn CrossChief Financial Officer | sold | 7,714at $25.14 | 20 Apr 2026filed 22 Apr 2026 |
| Mark FroimsonDirector | sold | 500at $21.81 | 17 Mar 2026filed 19 Mar 2026 |
| Jonathan SloninChief Medical Officer | sold | 3,261at $22.82 | 17 Mar 2026filed 19 Mar 2026 |
| Kristen WilliamsChief Administrative Officer | sold | 13,137at $20.53 | 2 Feb 2026filed 3 Feb 2026 |
| Lauren RikerSenior Vice President, Finance | sold | 4,000at $20.81 | 2 Feb 2026filed 3 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders231+14 on the quarter
New · exited40 · 26
Reported value$1.1B
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.reduced · filed 7 Aug 2026 | 6,705,809$170.1M | -29,534−0.4% |
| Doma Perpetual Capital Management LLCunchanged · filed 12 Aug 2026 | 2,777,794$70.5M | 00.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 2026 | 2,406,238$61.0M | -95,048−3.8% |
| DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026 | 2,103,245$53.4M | +42,648+2.1% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 2,059,977$52.3M | +140,367+7.3% |
| D. E. Shaw & Co., Inc.reduced · filed 14 Aug 2026 | 1,950,332$49.5M | -32,392−1.6% |
| RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026 | 1,733,801$44.0M | -91,700−5.0% |
| VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026 | 1,691,571$42.9M | -92,478−5.2% |
| GOLDMAN SACHS GROUP INCreduced · filed 14 Aug 2026 | 1,527,129$38.7M | -42,787−2.7% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 1,158,693$29.4M | +14,873+1.3% |
31 Mar 2023 – 30 Jun 2026
News
Pacira BioSciences jumps 44% on Viatris acquisition deal (PCRX:NASDAQ)seekingalpha.com · 8 Oct 2026Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition Newsinvestorideas.com · 8 Oct 2026Pacira Biosciences Snags $1.65 Billion Takeover Deal; Shares Flyinvestors.com · 8 Oct 2026Pacira BioSciences to Be Acquired by Viatris for $1.65Bmiragenews.com · 8 Oct 2026Why Pacira BioSciences Skyrocketed Todayaol.com · 8 Oct 2026Pacira Biosciences Snags $1.65 Billion Takeover Deal; Shares Flyinvestors.com · 8 Oct 2026Viatris Agrees To Acquire Pacira BioSciences In $1.65 Bln Cash Dealrttnews.com · 8 Oct 2026Viatris Agrees To Acquire Pacira BioSciences In $1.65 Bln Cash Dealrttnews.com · 8 Oct 2026
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.